EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine

Attia M Elbehi iD

Cambridge Prisms: Precision Medicine · 2025 · 3

DOI: 10.1017/pcm.2024.6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cambridge Prisms: Precision Medicine, online erschienen am 20.12.2024. Verfasst von Attia M Elbehi. Beteiligte Einrichtung: Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery and development of immune checkpoint inhibitors (ICIs) has revolutionised the management of human cancers. However, only a subset of patients responds to ICI therapy, even though immune evasion is a hallmark of cancer. Initially, treatment was administered to patients on the basis of expression levels of one of the targets of ICI therapy, programmed cell death ligand 1. In clinical trials, the high response rate of melanoma and non-small cell lung cancer patients to ICI therapy supported the basic premise of cancer immunotherapy, that tumour-specific mutated proteins trigger an immune response. Tumour mutational burden subsequently emerged as a potential biomarker for response to ICI therapy. This review summarises the evidence supporting the scientific rationale for TMB as a biomarker for ICI therapy and focuses on some of the major challenges associated with incorporation of TMB into routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorstargeted gene panelstumour mutation burdenwhole exome sequencing

Autor:innen und Institutionen

  • Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, UK.

ORCID-Profile: Attia M Elbehi

Zitieren

APA

Elbehi, A. M. (2025). The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine. Cambridge Prisms: Precision Medicine, 3. https://doi.org/10.1017/pcm.2024.6

Vancouver

Elbehi AM. The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine. Cambridge Prisms: Precision Medicine. 2025;3. doi:10.1017/pcm.2024.6

BibTeX
@article{Elbehi2025,
  author = {Elbehi, Attia M},
  title = {The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine},
  journal = {Cambridge Prisms: Precision Medicine},
  year = {2025},
  volume = {3},
  doi = {10.1017/pcm.2024.6}
}
Kostenlos starten →